INTRODUCTION

Trastuzumab (brand names Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera) is a humanized monoclonal antibody that binds to HER2 (ERBB2). Trastuzumab is used for the treatment of HER2-positive breast, gastroesophageal, and gastric cancers.

RGBiotech offers Trastuzumab expression plasmid vector. This plasmid vector is designed for expressing Trastuzumab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-188
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Trastuzumab
Brand Name(s): Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera
Classification: Monoclonal antibody (mAb)
Target: ERBB2, erb-b2 receptor tyrosine kinase 2, NEU; NGL; HER2; TKR1; CD340; HER-2; VSCN2; MLN 19; MLN-19; c-ERB2; c-ERB-2; HER-2/neu; p185(erbB2)
Amino Acid Sequence: Identical to DB00072

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 May;7(5):548-52.

[2] Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003 Sep 29;22(42):6570-8.

Contact Us